Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by M&T Bank Corp

M&T Bank Corp lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,435 shares of the biopharmaceutical company’s stock after buying an additional 1,096 shares during the quarter. M&T Bank Corp’s holdings in Regeneron Pharmaceuticals were worth $4,966,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in REGN. WPG Advisers LLC raised its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. Board of the Pension Protection Fund acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Caitlin John LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. FNY Investment Advisers LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 35 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:REGN opened at $721.05 on Thursday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $753.94 and a two-hundred day moving average of $739.52. The stock has a market cap of $76.23 billion, a P/E ratio of 17.57, a PEG ratio of 1.57 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the business earned $8.22 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.85 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating for the company in a research note on Thursday, April 30th. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Barclays reduced their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating for the company in a research note on Thursday, April 30th. Finally, Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $826.59.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,874 shares of company stock worth $3,013,262 in the last three months. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.